Annual Report 2003

Annual Report 2003 . Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies: -research and development of alfaHGA, a potential HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS® technology platform. -producing vaccines against influenza, allergies and Alzheimer's Disease through associated company VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/03/11/20040311BIT20630/wkr0007.pdf

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Documents & Links